Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8476 to 8490 of 9079 results

  1. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  2. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  3. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  4. AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428]

    Discontinued Reference number: GID-TA10809

    Technology appraisal guidance
    Discontinued

  5. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

    Technology appraisal guidance
    Discontinued

  6. Mastocytosis (systemic) - masitinib [ID781]

    Discontinued Reference number: GID-TA10019

    Technology appraisal guidance
    Discontinued

  7. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  8. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  9. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

    Medical technologies guidance
    Discontinued

  10. Seven day working

    Discontinued Reference number: GID-QS10108

    Quality standard
    Discontinued

  11. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued Reference number: GID-TA10110

    Technology appraisal guidance
    Discontinued

  12. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued Reference number: GID-TAG412

    Technology appraisal guidance
    Discontinued

  13. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued Reference number: GID-TAG420

    Technology appraisal guidance
    Discontinued

  14. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  15. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued Reference number: GID-TAG439

    Technology appraisal guidance
    Discontinued